METHODS
Animals Male Sprague-Dawley rats (Taconic, Germantown, NY, U.S.A.) weighing 200-225 g were used. Rats were housed in standard laboratory cages (2/cage) and kept in a temperature-and humidity-controlled colony room at least one week before use. Food and water were available ad libitum. This study was carried out in accordance with the Declaration of Helsinki and/or with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the U.S. National Institutes of Health.
Immunohistochemical identification of MOR -Rat brains were cut in serial sections (20 µm) as described elsewhere (Dacher et al. 2013) . Slides were fixed in 4% PFA for 5 min, washed in 1x PBS, and then blocked in 10% normal goat serum (NGS) containing 0.3% TritonX-100 in 1x PBS for 1 h. Sections were incubated in rabbit antigen affinity purified anti-MOR 349-398 (3 µg/ml) in carrier solution (0.5% NGS in 0.1% Triton X-100 in 1x PBS) overnight at room temperature. Preincubation of anti-MOR 349-398 (3 µg/ml) with 0.1 µM GST-MOR (the antigen used to raise the antibody) completely blocked the recognition of MOR by the anti-MOR . After rinsing in 1xPBS, sections were incubated for 2 h in Alexa Flour 488-labeled goat anti-rabbit IgG (1:200) .
DAMGO-stimulated [ 35 S]GTPγS Binding to SHSY5Y Cell Membranes -DAMGO-stimulated [
35 S]GTPγS binding to SHSY5Y cell membranes was performed as previously described (Traynor & Nahorski 1995 (Kazmi & Mishra 1987) .
Solubilization of rat brain membranes.
Routinely, membranes were incubated in buffer containing 50 mM Hepes (pH 7.4), 100 mM NaCl, 2 mM Tris.EDTA, 1 mM Tris.EGTA, 5 mM MgCl 2 and protease inhibitors (routinely: PMSF, 0.1 mM; leupeptin, 1 µM; soyprotein inhibitor, 5 µg/ml; pepstatin A, 1 µM; and aprotonin, 4 µg/ml) and phosphatase inhibitors (Sigma P 0044) (Buffer A) with 1 µM DAMGO and 0.3 µM RGS4 for 10 min at 30ºC prior to their solubilization unless otherwise indicated in figure legends. Rat brain membranes, solubilized in 10 mM CHAPS detergent, were passed through a Sephadex G50 column (15 x 0.75 cm) preequilibrated with Buffer A containing 4 mM CHAPS. Solubilized rat brain membranes were used for both MOR immunoprecipitation studies and for studies of the interaction between solubilized G proteins and His 6 RGS4 attached to Ni 2+ -NTA agarose. For Ni 2+ -NTA pull down experiments, rat brain membranes were not preincubated with a mu opioid receptor agonist or RGS4.
[ 3 H]DAMGO binding to immunoprecipitated MOR was performed as previously described (ChaleckaFranaszek et al. 2000) . The inclusion of protease inhibitors was critically important for maintaining high affinity, G protein-dependent, specific [ 3 H]DAMGO binding activity.
Preparation of recombinant RGS4 -His 6 RGS4 was expressed in JM109 E. coli, and His 6 RGS4 was extracted (in the presence of protease inhibitors, Sigma P 8849) on Ni 2+ -NTA agarose resin. The predominant product ran as a single band of ~26 kDa on a 12% SDS-PAGE gel. Routinely, the 26 kDa band made up 75-90% of all protein stained with Commassie blue. The 26 kDa band was specifically identified in immunoblots with antibodies that were raised against the C-terminal 36 amino acids of RGS4 ) or ABT17 (anti-RGS4 1-205 , Millipore). The molar concentration of His 6 RGS4 used in experiments was determined from the purity of His 6 RGS4, the amount of protein (determined by the BioRad protein assay), and the molecular weight of His 6 RGS4 of 26 kDa.
MOR and RGS4 Antibodies -All antibodies directed against MOR and RGS4 were generated in rabbits using standard techniques (Duncroft Inc. Lovettsville, VA). Polyclonal antibodies were raised against glutathione-S-transferase (GST) fused to either 61 amino acids near the N-terminal of rat MOR (GST-MOR 10-70 ), the C-terminal 59 amino acids of MOR ) or the C-terminal 50 amino acids of MOR (anti-MOR 349-398 ) as previously described (Chalecka-Franaszek et al. 2000) . Each of these anti-MOR antibodies was able to identify MOR in sections of rat brain, as is shown for anti-MOR 349-398 in SuppInfo Fig. 1 ). Polyclonal anti-RGS4 170-205 was raised against glutathione-S-transferase fused to the Cterminal 36 amino acids of the rat RGS4 ). See SuppInfo Table 1 and SuppInfo Fig. 3 for details about anti-RGS4 . Antibodies used for immunoblots (anti-MOR 349-398 at 0.2 µg/ml and anti-RGS4 170-205 at 2 µg/ml) were antigen-affinity purified. The purified antibodies were dialyzed extensively at 4ºC against phosphate-buffered saline (pH 7.4) and stored at -20ºC.
Immunoblots The presence of endogenous MOR was detected with antigen affinity-purified anti-MOR 349-398 at a concentration of 0.2 µg/ml (Chalecka-Franaszek et al. 2000) . A mouse secondary antibody against rabbit light chain of IgG, along with donkey anti-mouse tagged with horseradish peroxidase, was used to detect anti-MOR . Inclusion of the fusion protein GST-MOR 349-398 (0.3 µM) blocked recognition of endogenous MOR by anti-MOR . The presence of endogenous Goα was detected with antiserum #3975 at a dilution of 1:750 (Cell Signaling Technology, Danvers, MA). The same secondary system that was used to detect anti-MOR 349-398 was used to detect anti-Goα. The presence of co-immunoprecipitated His 6 RGS4 (mol. wt. ~26 kDa) or endogenous RGS4 (~25 kDa) was detected with 2 µg/ml of antigenaffinity-purified anti-RGS4 . Secondary anti-rabbit heavy chain antibody was used to detect anti-RGS4 . Inclusion of the 0.3 µM GST-RGS4 170-205 blocked recognition of recombinant RGS4 by antibody anti-RGS4 . Known standard amounts of His 6 RGS4 (0.5 to 10 ng) were subjected to SDS PAGE along with His 6 RGS4 co-immunoprecipitated with MOR (IP with anti-MOR 10-70 ). The densities of His 6 RGS4 bands were quantified using ImageJ software. Nanogram values of co-immunoprecipitated His 6 RGS4 bands were determined by extrapolation using nonlinear regression analysis of known RGS4 standards run on the same gel.
His 6 RGS4/Ni
2+ -NTA agarose pull-down experiments -Rat brain membranes (without any pretreatment) were solubilized and passed through Sephadex G50 columns as in Methods of Supporting Information. Solubilized membranes were incubated with end-over-end mixing for 1 h at 4ºC in buffer A with 100 ng of His 6 RGS4 pre-attached to 50 µl of Ni 2+ -NTA agarose resin in a final volume of 1 ml. Samples were centrifuged for 2 min, supernatants were discarded, and pellets were washed 4 times. Pellets were resuspended in 100 µl of SDS sample buffer and placed in boiling water for 2 min. Ten µl aliquots were subjected to SDS PAGE and immunoblotting as indicated.
SHSY5Y cell culture -Undifferentiated SHSY5Y neuroblastoma cells were purchased from American Type Cell Culture (Manassas, VA). SHSY5Y cells were grown in 75 mm flasks to ~80% confluency in Dulbecco's Modification of Eagle's Medium containing 4.5 g/L glucose, 1% Glutamax, penicillin (100 units/ml), streptomycin (100 µg/ml), and 15% fetal calf serum. Pretreatment of cells with 1 µM DAMGO for 1 hour was found to be optimal for testing RGS4 in cell homogenates (SuppInfo Table 2 ). Therefore, SHSY5Y cells were routinely incubated for 1 hour with 1 µM DAMGO before RGS4 was tested in the adenylyl cyclase assay, in the Adenylyl Cyclase Assay -The effects of His 6 RGS4 on mu opioid receptor-mediated inhibition of adenylyl cyclase activity was determined as previously described (Gosse et al. 1989) .
SUPPORTING RESULTS AND DISCUSSION
Recognition of MOR in sections of rat brain All three of anti-MOR antibodies (SuppInfo Table 1 ) were capable of immunohistochemically identifying MOR in sections of rat brain. For example, it is evident in SuppInfo Figure 1 that anti-MOR 349-398 specifically identified MOR in the medial habenula (A), the shell of the nucleus accumbens (B), the caudate putamen (C) and the amygdala (D), areas of the brain where opiates cause analgesia (A), reward (B & C) and modulation of anxiety (D). Unfortunately, these MOR antibodies are not useful in mice because, even though they appeared to recognize MOR in sections of mouse brain caudate putamen (SuppInfo Fig. 1E ), there was an unacceptable amount of nonspecific staining in sections of MOR -/-mouse brain (SuppInfo Fig. 1F ). Fig. 2C ), the inclusion of DAMGO, but not naltrexone, during the solubilization and immunoprecipitation with anti-MOR 349-398 increased the amount of Goα coimmunoprecipitating with MOR by approximately 2-fold (SuppInfo Fig. 2C ; in a total of 5 experiments, the inclusion of DAMGO during IP with anti-MOR 349-398 caused a 2.2-fold increase in Goα, p = 0.015). We speculate that DAMGO also increases the amount of Gi1 and Gi3, two other G proteins that have been shown to co-IP with MOR. In subsequent experiments, anti-MOR 10-70 was used to immunoprecipitate MOR to ensure that the antibody would not interfere with the binding of proteins to the intracellular surface of MOR. 170-205 (a.k.a. 1554 ) Anti-RGS4 170-205 was generated against a fusion protein composed of glutathione-S-transferase fused on its C terminus to the last 36 amino acids of RGS4 ). Anti-RGS4 170-205 (a.k.a. 1554, SuppInfo Table 1 ) can detect as little as 0.5 ng of recombinant RGS4. We often include a 1 ng sample of His 6 RGS4 on a gel to aid in the location of His 6 RGS4 that has been co-immunoprecipitated with MOR. In SuppInfo Fig. 3A , we showed that anti-RGS4 170-205 easily detected 1 ng and 10 ng His 6 RGS4, but it did not detect His 6 RGS19. On the other hand, anti-RGS19 (purchased from Fitzgerald) did not detect RGS4 but did detect RGS19. Anti-RGS4 can also detect endogenous RGS4 in rat brain membranes. Anti-RGS4 170-205 can also detect endogenous RGS4 (arrows) in rat brain membranes (SuppInfo Fig 3B and Fig. 3 ). The blot shown in SuppInfo Fig. 3B is an over-exposure of the blot shown in Fig. 3B ). The over-exposure reveals that both our antibody (Anti-RGS4 170-205 ) and ABT17 can identify endogenous RGS4.
Immunoprecipitation of the MOR/G protein complex

Specificity of anti-RGS4
GTPγS-stimulated binding of Gi3 and Go to RGS4
The current study focused on the interactions among MOR, RGS4 and Go, but certainly other G proteins interact with MOR and RGS4. Therefore, we tested that ability of GTPγS to stimulate the binding of other G proteins to His 6 RGS4. His 6 RGS4 was incubated with solubilized rat brain membranes, and His 6 RGS4 was 'pulled out of solution' with Ni 2+ -NTA agarose resin. The pulled-down material was then screened for G proteins and RGS4. In this experiment, 0.3 µM GTPγS stimulated the binding of Goα and Gi3α to RGS4 (SuppInfo Fig. 4) . GTPγS did not affect the binding of Gi2α, Gsα or Gqα to RGS4. Previous studies have reported that aluminum fluoride stimulated the binding of Giα/Goα-type G proteins and Gqα to RGS4. In the current study, the lack of effect of GTPγS on Gq binding to RGS4 may be due to the lower affinity of Gqα for GTPγS. We have previously reported that the EC50 of GTPγS was ~40-fold higher in activating phospholipase C (via Gq) than in inhibiting adenylyl cyclase activity (via Go/Gi-type G proteins) (Aub et al., 1986) . Perhaps a substantially higher concentration of GTPγS is needed to stimulate Gq binding to RGS4. Unfortunately, we have not yet obtained a useful antibody that detects Gi1α. A more extensive investigation of the influence of MOR on the interactions of multiple G proteins with RGS4 and RGS19 is in progress.
Concentration-dependent attenuation of MOR signaling by RGS4
RGS4 caused a concentrationdependent attenuation of DAMGO-mediated inhibition of adenylyl cyclase activity in the presence of GTP (SuppInfo Figure 5) . In the absence of RGS4, 1 µM DAMGO plus 10 µM GTP and 1 µM DAMGO plus 1 µM GTPγS caused a 60.4 ± 2.97 and 52.7 ± 2.57% inhibition of adenylyl cyclase activity, respectively. The addition of increasing concentrations of RGS4 caused a concentration-dependent attenuation of DAMGO (plus GTP)-mediated inhibition of adenylyl cyclase (EC50 of RGS4 = 8.36 ± 0.15 x 10 -8 M). In the presence of 3 µM RGS4, DAMGO inhibited forskolin-stimulated adenylyl cyclase activity by only 21.8 ± 2.27%. In contrast, RGS4 failed to attenuate GTPγS-mediated inhibition of adenylyl cyclase activity.
His 6 tag did not contribute to the ability of His 6 RGS4 to attenuate MOR-mediated inhibition of adenylyl cyclase activity
To ensure that the His 6 tag of His 6 RGS4 was not contributing to the ability of His 6 RGS4 in diminishing the efficacy of DAMGO, full-length RGS4 (without His 6 ) was sub-cloned into a GST fusion protein vector (pQEX-2T). RGS4 was cut from GST-RGS4 with thrombin, and free GST was removed by absorption onto a glutathione resin. RGS4 prepared in this way attenuated the efficacy but not the potency of DAMGO in inhibiting adenylyl cyclase activity (SuppInfo Fig. 6A ) just as was seen with His 6 RGS4 (Fig. 5, left panel) .
Aspects of the MOR/G protein complex functioning not affected by RGS4
RGS4 failed to affect GTPγS-mediated inhibition of adenylyl cyclase activity (SuppInfo Fig. 6B ). In concentration-response curves, the EC50s of GTPγS were 31.2 nM M and 33.2 nM in the absence and presence of 1 µM RGS4, respectively. GTPγS inhibited adenylyl cyclase activity to 43.7% of maximal activity and 39.4% of maximal activity, in the absence and presence of 1 µM RGS4, respectively. Also, RGS4 did not significantly alter DAMGO-stimulated binding of [ 35 S]GTPγS to G proteins associated with SHSY5Y cell membranes (SuppInfo Fig. 6C ). This assay measures the ability of MOR activation by DAMGO to cause GDP to dissociate from cognate G proteins and thus allow [
35 S]GTPγS to bind to these G proteins. In three independent experiment, RGS4 failed to affect either the efficacy or the potency of DAMGO is stimulating [
35 S]GTPγS binding to SHSY5Y membranes. Finally, RGS4 did not affect the binding of [ 3 H]DAMGO to MOR in SHSY5Y cell membranes (SuppInfo Fig. 6D ).
SuppInfo ) identifies endogenous MOR in western blots. All 3 anti-MOR antibodies can immunohistochemically identify MOR in rat. We routinely use antigen-affinity purified 1414 for IHC although 1390 and 1404 identify the same structures in sections of rat brain.
Antigen-affinity purified anti-RGS4 (1554) is useful for western blotting of recombinant & endogenous RGS4. It can detect as little as 0.5 ng of His 6 RGS4, and occasionally even smaller amounts of His 6 RGS4. Recognition of His 6 RGS4 is blocked by preincubating anti-RGS4 170-205 with 0.1 µM GST-RGS4 170-205 (see Fig. 1A ) but not with 0.1 µM GST (not shown). In SuppInfo Fig. 3 , anti-RGS4 170-205 was shown to recognize His 6 RGS4 but not His 6 RGS19 in a western blot. Note: although anti-RGS4 170-205 was tested only against RGS19 for cross-reactivity, it is very unlikely that anti-RGS4 170-205 will recognize any other RGS because the amino acid sequence in the C-tail of RGS4 (170-205) is unique to RGS4 among known RGS proteins (this region is outside of the homologous 'RGS domain'). Both anti-RGS4 170-205 (a.k.a. 1554) and anti-RGS4 1-205 (a.k.a. ABT17 or U1079), a well-characterized antibody that is known to recognize endogenous RGS4 in western blots, recognized His 6 RGS4 and endogenous RGS4 from brain membranes and also His 6 RGS4 and endogenous RGS4 in material that co-immunoprecipitated with MOR (Fig. 3A) . When the same experiment was performed without recombinant RGS4, ABT17 recognized only the lower weight band in material co-immunoprecipated with anti-MOR 10-70 (Fig. 3B) . In IHC assays, anti-RGS4 170-205 binds extensively to nuclear material that is not RGS4 throughout rat brain. Anti-RGS4 170-205 also binds extensively to nuclear material in sections of RGS4 -/-mouse brain (not shown). Therefore, anti-RGS4 170-205 cannot be used for IHC. was also ineffective in immunoprecipitating recombinant RGS4.
SuppInfo Table 2. Pretreatment of SHSY5Y cells with DAMGO enhanced the ability of RGS4 to attenuate DAMGO-mediated inhibition of adenylyl cyclase activity in cell homogenates.
Percent of maximal adenylyl cyclase activity Control 1 µM DAMGO 1 µM DAMGO & 1 µM RGS4 Homogenate from untreated cells 100 ± 4.5 33.3 ± 3.7 52.9 ± 1.7 Homogenate from DAMGO treated cells 100 ± 3.6 36.8 ± 2.8 68.0 ± 1.9* Cells were either untreated or treated for 1 h with 1 µM DAMGO. DAMGO was removed by incubating the cells in fresh media containing no DAMGO for 30 min. Cells were then rinsed 3x in PBS and homogenized in homogenizing buffer as described in Methods. Homogenates were incubated on ice for 10 min with or without 1 µM RGS4. Then homogenates were rapidly added to tubes containing components of the adenylyl cyclase assay, and racks of tubes were transferred to a 30ºC water bath for 10 min and then to boiling water to terminate the assay. Levels of cAMP were determined as described in Methods. Data are expressed as the percent of maximal forskolin-stimulated adenylyl cyclase activity 
SUPPINFO FIGURE LEGENDS
SuppInfo Figure 1 . identifies MOR immunohistochemically in sections of rat brain. All images shown in this figure were probed for MOR with antigen-affinity purified anti-MOR 349-398 (ID# 1414), but anti-MOR 340-398 and anti-MOR 10-70 work equally well in identifying MOR in rat brain sections. Panels A -D. Rat brains cut in serial sections (20 µm) were prepared as described elsewhere (Dacher et al. 2013) . Panel A. MOR is expressed in high density in the medial habenula where it contributes to opiate analgesia (Darcq et al. 2012) . Panel B. MOR in the shell of the nucleus accumbens is involved in the reward pathway (Lutz & Kieffer 2013) . Panel C. MORs on medium spiny neurons (MSN) in caudate putamen appear as patches; MOR on MSN play a role in opiate reward (Cui et al. 2014) . Panel D. MOR on neurons in the amygdala modulate anxiety (Wilson & Junor 2008 SuppInfo Figure 2 . Immunoprecipitation of the MOR/G protein complex Panel A. Rat brain membranes were incubated for 10 min on ice with 1 µM DAMGO and then solubilized with 10 mM CHAPS and processed as described in Methods. The solubilized material was subjected to immunoprecipitation with normal rabbit serum (NRS) or three different anti-sera directed against MOR (anti-MOR 340-398 , anti-MOR 349-398 or anti-MOR 10-70 ) that had been cross-linked to Protein A Sepharose. Following the immunoprecipitation procedure, a 20 µl aliquot (1/6 of the total immunoprecipitate) of each sample was subjected to SDS-PAGE on a 12% gel. Proteins were transferred to a nitrocellulose membrane, and portions of the nitrocellulose membrane were screened as follows: the upper portion of the membrane (between the 52 kDa and 90 kDa markers) was screened for MOR with anti-MOR , and the lower portion of the membrane (between the 31 kDa and 52 kDa markers) was screened for Goα with antiserum #3975 (Cell Signaling Technology, Danvers, MA). MOR was detected as a smear running between ~54 to 70 kDa; inclusion of 0.3 µM GST-MOR 349-398 (the antigen used to raise anti-MOR 349-398 ) blocked detection of most of the smear believed to be MOR (right top panel). Panel B. Each anti-MOR antibody (and normal rabbit serum) that was used in panel A was also tested for its ability to immunoprecipitate (DAMGO) but not an antagonist (naltrexone) increased the co-immunoprecipitation of Goα. Rat brain membranes were incubated without a ligand (Control) or with either 1 µM DAMGO or 1 µM naltrexone during immunoprecipitation with anti-MOR 349-398 . The immunoprecipitated material was subjected to SDS-PAGE and immunoblotting with anti-Goα. The inclusion of DAMGO, but not naltrexone, caused a significant increase (2.2-fold) in the amount of Goα co-immunoprecipitated with MOR (unpaired, two-tailed t test, p=0.034). Results shown are from 3 independent experiments. ImageJ software was used to quantify the densities of bands corresponding to Goα.
SuppInfo Fig. 3 . Specificity of anti-RGS4 in western blots and ability of anti-RGS4 to recognize endogenous RGS4 A. and anti-RGS10 (Fitzgerald) were compared for their abilities to recognize His 6 RGS4 and His 6 RGS19 in western blots. Each antibody recognized only the appropriate RGS protein. B. Anti-RGS4 170-205 also recognized endogenous RGS4 (arrow) in rat brain membranes (left lane of each blot). The commercially available antibody, ABT17, also recognized endogenous RGS4. The image shown in B is an over-exposure of the blot shown in Fig. 3 .
